Brokerages Set Bioventus Inc. (NASDAQ:BVS) PT at $14.75

Shares of Bioventus Inc. (NASDAQ:BVS) have been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $14.75.

BVS has been the subject of several recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Barrington Research reaffirmed an “outperform” rating and set a $14.00 price target on shares of Bioventus in a research report on Tuesday, June 30th. CJS Securities began coverage on Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a report on Tuesday, June 16th.

Bioventus Trading Up 2.6%

Shares of NASDAQ:BVS opened at $11.88 on Wednesday. The company’s 50-day moving average price is $9.95 and its two-hundred day moving average price is $9.21. Bioventus has a one year low of $5.81 and a one year high of $12.53. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. The stock has a market capitalization of $992.46 million, a PE ratio of 28.98, a price-to-earnings-growth ratio of 1.48 and a beta of 0.65.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.06. The company had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities analysts forecast that Bioventus will post 0.79 EPS for the current fiscal year.

Institutional Trading of Bioventus

A number of large investors have recently added to or reduced their stakes in BVS. Caitong International Asset Management Co. Ltd increased its stake in shares of Bioventus by 17,156.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after purchasing an additional 5,490 shares during the last quarter. Prelude Capital Management LLC acquired a new stake in Bioventus in the 3rd quarter valued at about $74,000. Mercer Global Advisors Inc. ADV bought a new position in Bioventus during the third quarter worth about $78,000. SG Americas Securities LLC bought a new position in Bioventus during the fourth quarter worth about $80,000. Finally, Brooklyn Investment Group acquired a new position in Bioventus during the fourth quarter worth approximately $91,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.